Immunogenicity of virus-like particle vaccine candidates against SARS-CoV-2 infection

References

1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24:91–98 [View Article] [PubMed]
   [Google Scholar]
2. Hui DS, E IA, Madani TA, Ntoumi F, Kock R et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91:264–266 [View Article] [PubMed]
   [Google Scholar]
3. Chen T, Wu D, Chen H, Yan W, Yang D et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368:m1091 [View Article] [PubMed]
   [Google Scholar]
4. Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care 2021; 25:244 [View Article] [PubMed]
   [Google Scholar]
5. Sanyaolu A, Okorie C, Marinkovic A, Haider N, Abbasi AF et al. The emerging SARS-CoV-2 variants of concern. Ther Adv Infect Dis 2021; 8:20499361211024372 [View Article] [PubMed]
   [Google Scholar]
6. Grgacic EVL, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006; 40:60–65 [View Article] [PubMed]
   [Google Scholar]
7. Sultana R, Stahelin RV. Strengths and limitations of SARS-CoV-2 virus-like particle systems. Virology 2025; 601:110285 [View Article] [PubMed]
   [Google Scholar]
8. Hao X, Yuan F, Yao X. Advances in virus-like particle-based SARS-CoV-2 vaccines. Front Cell Infect Microbiol 2024; 14:1406091 [View Article] [PubMed]
   [Google Scholar]
9. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012; 31:58–83 [View Article] [PubMed]
   [Google Scholar]
10. Hemmati F, Hemmati-Dinarvand M, Karimzade M, Rutkowska D, Eskandari MH et al. Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2. Biotechnol Lett 2022; 44:45–57 [View Article] [PubMed]
    [Google Scholar]
11. Plescia CB, David EA, Patra D, Sengupta R, Amiar S et al. SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles. J Biol Chem 2021; 296:100103 [View Article] [PubMed]
    [Google Scholar]
12. Hsieh P-K, Chang SC, Huang C-C, Lee T-T, Hsiao C-W et al. Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent. J Virol 2005; 79:13848–13855 [View Article] [PubMed]
    [Google Scholar]
13. Nguyen HT, Falzarano D, Gerdts V, Liu Q. Construction of a noninfectious SARS-CoV-2 replicon for antiviral-drug testing and gene function studies. J Virol 2021; 95:e0068721 [View Article] [PubMed]
    [Google Scholar]
14. Shi J, Wang G, Zheng J, Verma AK, Guan X et al. Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern. NPJ Vaccines 2022; 7:169 [View Article] [PubMed]
    [Google Scholar]
15. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 2020; 12:513 [View Article]
    [Google Scholar]
16. Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep 2021; 35:109292 [View Article] [PubMed]
    [Google Scholar]
17. Liu X, Drelich A, Li W, Chen C, Sun Z et al. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Vaccine 2020; 38:7205–7212 [View Article]
    [Google Scholar]
18. Yi C, Sun X, Ye J, Ding L, Liu M et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol 2020; 17:621–630 [View Article]
    [Google Scholar]
19. Denning W, Das S, Guo SQ, Xu J, Kappes JC et al. Optimization of the transductional efficiency of lentiviral vectors: effect of sera and polycations. Mol Biotechnol 2013; 53:308–314 [View Article] [PubMed]
    [Google Scholar]
20. Nguyen HT, Falzarano D, Gerdts V, Liu Q. Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam. Microbiol Spectr 2024; 12:e0095924 [View Article] [PubMed]
    [Google Scholar]
21. Prasad S, Potdar V, Cherian S, Abraham P, Basu A et al. Transmission electron microscopy imaging of SARS-CoV-2. Indian J Med Res 2020; 151:241–243 [View Article] [PubMed]
    [Google Scholar]
22. Felberbaum RS. The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol J 2015; 10:702–714 [View Article] [PubMed]
    [Google Scholar]
23. Li M, Wang Y-F, Wang Y, Gao H, Li N et al. Immune responses induced by a BacMam virus expressing the E2 protein of classical swine fever virus in mice. Immunol Lett 2009; 125:145–150 [View Article] [PubMed]
    [Google Scholar]
24. Coutelier JP, van der Logt JT, Heessen FW, Warnier G, Van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 1987; 165:64–69 [View Article] [PubMed]
    [Google Scholar]
25. Moran TM, Park H, Fernandez-Sesma A, Schulman JL. Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 1999; 180:579–585 [View Article] [PubMed]
    [Google Scholar]